The case for & against
Bull & Bear analysis
Bullish
Bausch + Lomb Corporation (NYSE: BLCO) is a global leader in eye health, offering a wide range of surgical, pharmaceutical, and consumer vision care products. The company operates at the forefront of ophthalmic innovation while capitalizing on long-term trends, including an aging population and increasing demand for premium surgical products. Bausch + Lomb is renowned for its commitment to quality and safety across its diverse portfolio, including the rising innovations in dry eye treatment and advanced surgical solutions.
Bull says
- ↑Q1 revenue hit $1.244 B (+6% YoY); adj. EBITDA $200 M (+59%) with 16.1% margin
- ↑Dry eye segment driving guidance to $5.42–5.52 B, Mibo +110% and Zydra +14% YoY
- ↑Gross margin improved to 61.2% (+170 bps); targeting 19% adj. EBITDA margin in 2026
- ↑R&D spend rose 17% YoY to $101 M; launching innovations like EyeGility™ Inserter
- ↑Attractive valuation with high earnings yield and favorable book-to-price
- ↑Rising institutional ownership hints at buyback support and price resilience
Bear says
- ↓Negative profitability factors limit revenue-to-profit conversion and deter investors
- ↓Invista IOL recall impedes surgical recovery; confidence rebuild may take quarters
- ↓Dry eye market intensifies; new entrants threaten share and pricing power
- ↓Analyst revisions are down, signaling lower future earnings and slower growth
- ↓Elevated volatility and liquidity challenges raise short-term financial risks
- ↓Smaller size vs. peers could hamper competitive positioning and scale advantages
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-17-2026neutral
Transcript signals
Bull points
- Bausch & Lomb is a durable growth company, operating in a category with long-term tailwinds, aging populations, rising myopia, and a move toward premium products in cataract surgery.
- We're growing consistently across pharmaceuticals, surgical, and vision care. What is changing and what matters most for shareholders is the quality of that growth.
- 6% year-over-year constant currency revenue growth demonstrates the consistency I referenced earlier.
Bear points
- Our surgical business delivered growth in the quarter, though the results came in below expectations, primarily due to temporary factors, including weather-related disruption to cataract procedures and reimbursement pressures in select markets.
- First quarter revenue was $228 million, an increase of 1%, lapping 11% growth in the prior year. As Brent mentioned, the surgical business was impacted by, among other things, one-time weather-related disruptions and a rebuild of the US Field Force.
- non-GAAP financial measures and ratios
Read full transcript analysis ›